CAN CSA Z11135-15: Sterilization of Health Care Products — Ethylene Oxide — Requirements for Development, Validation and Routine Control

CAN CSA Z11135-15 specifies requirements for the development, validation, and routine control of ethylene oxide (EO) sterilization processes for health care products. This Canadian standard, published by the CSA Group and recognized by Health Canada, is the national adoption of ISO 11135:2014 with national deviations. It establishes a comprehensive framework for ensuring sterility and safety of EO-sterilized medical devices, pharmaceutical packaging, and other health-related products.

As a normative reference for medical device marketers seeking a Medical Device Licence (MDL) under the Canadian Medical Devices Regulations (SOR/98-282), CAN CSA Z11135-15 outlines the process definition, validation protocols, routine monitoring, and quality management integrations required for compliant EO sterilization. This article provides an in-depth analysis of its structure, technical requirements, and practical implementation considerations.

Scope and Applicability

CAN CSA Z11135-15 applies to manufacturers and contract sterilizers performing EO sterilization for products designated as sterile. The standard covers:

Processes where EO is the sterilizing agent (either as pure gas or mixtures with inert diluents).
All stages from pre-conditioning through exposure to aeration.
Sterilization of single-use and reusable medical devices, pharmaceutical components, and biological indicators for validation.

It excludes processes involving other sterilizing methods (dry heat, steam, radiation) and does not address environmental monitoring of the sterilization area. The standard aligns with ISO 11135:2014 but adds clarifications relevant to Canadian regulatory expectations, including references to the Canadian Environmental Protection Act regarding EO emissions.

Tip: When adopting CAN CSA Z11135-15, manufacturers should verify the latest national deviations published by CSA Group, as Canadian regulations (e.g., for EO residual limits and worker exposure) can differ from the international baseline.

Technical Requirements for EO Sterilization

Process Definition

Before validation, the manufacturer must define the sterilization process in a formal Process Definition Document. This includes:

Product Description: Physical and chemical characteristics of each product family, packaging, and loading configuration.
Sterilization Conditions: Target gas concentration, temperature, humidity, exposure time, and aeration parameters.
Acceptance Criteria: Maximum allowable residuals (ethylene oxide and ethylene chlorohydrin), sterility assurance level (SAL), and functional/performance tests.
Risk Analysis: Identification of factors affecting sterility (microbial load, bioburden resistance, product complexity).

Validation Requirements

The standard mandates a three-stage validation protocol aligned with ISO 11135:2014:

Installation Qualification (IQ): Verification that sterilization equipment meets specifications (gas supply, temperature sensors, humidity control, vacuum system).
Operational Qualification (OQ): Demonstration that the equipment operates within defined limits across all cycles. Includes load mapping to determine the coldest/hottest spots for temperature distribution.
Performance Qualification (PQ): Biological challenge tests using a sublethal half-cycle approach. The half-cycle is established so that no biological indicator (BI) shows growth; the full cycle is typically twice the half-cycle. Additional full-cycle tests quantify EO residuals and product compatibility.

Success Criteria: Approval of validation is based on SAL of 10^–6, unless risk assessment justifies a higher SAL. BIs (Bacillus atrophaeus spores) must show no growth after half-cycle exposure.

Routine Monitoring and Control

Once validated, the standard requires continuous monitoring of each production batch:

Parameter	Monitoring Frequency	Acceptance Criteria
Gas Concentration	Every load	Within ±5% of set point
Temperature (T)	Continuous per probe	Set point ±1°C
Relative Humidity (RH)	Every load	Set point ±5%
Exposure Time	Per cycle	Set point +0% / -1%
Aeration Temperature/Time	Per load	Residuals below defined limits

Warning: Inadequate aeration can lead to toxic EO residuals exceeding permissible limits (e.g., 250 µg/g for devices contacting skin). Aeration failure was cited in multiple Health Canada safety alerts. Always validate aeration with worst-case product load configurations.

Implementation Highlights

Equipment Considerations

Sterilizers must be constructed with materials resistant to EO corrosion and be leak-tight. The standard emphasizes proper chamber calibration, including:

Calibrated thermocouples for temperature mapping.
Gas concentration measurement via load cells or infrared sensors.
Humidity injection systems with verification of steam quality.

Routine maintenance should follow a documented schedule covering gas line filters, vacuum pump oils, and sensor drift checks.

Biological Indicators

BIs with a known D-value (resistance) and population (≥1.0×10⁶ spores per indicator) are required. User qualification of BI lots is mandatory; the manufacturer must demonstrate that the BI D-value is at least as high as the product’s bioburden resistance. Where the half-cycle is based on a BI with D-value exceeding the worst-case product D-value, the standard permits a reduced cycle time.

Safety Note: Ethylene oxide is flammable (3.6–100% by volume in air) and a known carcinogen. EO handling areas must be designed for safe ventilation, gas detection, and emergency shutdown per local codes. The standard references safety requirements from CSA Z11135-15 Annex E (informative) but does not replace workplace safety regulations.

Product Release

Every batch must meet the defined sterility and residual criteria before release. Release decisions integrate:

Parametric release (if regulatory approval allows) based on continuous monitoring.
Biological indicator results from the lot.
Residual testing from a sample load (if parametric release is not used).

Companies must maintain a Sterility Assurance File that includes validation records, deviation reports, and change control documentation.

Compliance Notes for Canadian Manufacturers

Health Canada recognizes CAN CSA Z11135-15 as a consensus standard for demonstrating compliance with the Medical Devices Regulations. Key regulatory expectations for audit include:

Quality Management System Integration: The standard must be implemented within a compliant QMS (e.g., CAN CSA Z13385-16 for ISO 13485:2016). Document control, training, and CAPA procedures must link directly to sterilization process changes.
Environmental Reporting: EO emissions fall under the Canadian Environmental Protection Act, 1999 (CEPA). Manufacturers must report EO releases if thresholds are exceeded.
Residual Limits: Health Canada references limits from ISO 10993-7 (e.g., 40 µg/g for individual EO, 9 µg/g for ECH for prolonged contact). Specific devices may require lower limits based on clinical use.
Device Tracking: For implantable devices, Health Canada expects traceability of sterilization batch records for 10 years.

Audit Checklist: During a CSA or regulatory audit, be prepared to present the Process Definition Document, validation report (IQ/OQ/PQ), last 12 months of routine monitoring graphs, change control records, and training files for all personnel involved in sterilization.

As of 2026, the Canadian sterilization landscape prefers CAN CSA Z11135-15 over ad hoc protocols. Manufacturers exporting to multiple regions should note that this standard is technically equivalent to EN ISO 11135:2014 and ANSI/AAMI/ISO 11135:2014, simplifying harmonization under 13485 QMS.

This article reflects the standard CAN CSA Z11135-15 as published in 2015 and current regulatory practices as of 2026. Users should confirm the latest official version issued by the CSA Group.

Frequently Asked Questions

Q: Which products are covered by CAN CSA Z11135-15?
A: The standard applies to any health care product—including medical devices, pharmaceutical packaging, and in vitro diagnostic kits—that is intended to be sterilized using ethylene oxide. It covers the entire sterilization process from pre-packaging to final release.

Q: How does CAN CSA Z11135-15 relate to ISO 11135?
A: CAN CSA Z11135-15 is the Canadian adoption of ISO 11135:2014. It is technically identical but includes national deviations such as references to Health Canada regulatory requirements and Canadian environmental standards for EO emissions.

Q: What is the required sterility assurance level (SAL) under this standard?
A: The default requirement is a sterility assurance level of 10^-6 (one non‑sterile unit in one million). However, the standard allows a different SAL if justified by a documented risk assessment (e.g., for surface‑sterilized instruments with low exposure).

Q: Can I use parametric release under CAN CSA Z11135-15?
A: Yes, parametric release is permitted if the manufacturer obtains regulatory approval from Health Canada. It requires validated online monitoring of all critical parameters (gas concentration, temperature, humidity, time). The standard defines the conditions for eliminating biological indicator testing for each load.

📥 Standard Documents Download

🔒

Please wait 10 seconds, the download links will appear after the ad loads